Dr. Agarwal on the STAMPEDE and LATITUDE Trials for Prostate Cancer

Neeraj Agarwal, MD
Published: Thursday, Jun 22, 2017



Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the STAMPEDE and LATITUDE trials for patients with prostate cancer.

The phase III STAMPEDE and LATITUDE trials have changed the standard of care for patients with newly diagnosed metastatic hormone-sensitive prostate cancer, states Agarwal.

Both trials combined abiraterone acetate (Zytiga) plus prednisone plus standard androgen deprivation therapy, explains Agarwal. Given the data from the trial, abiraterone plus prednisone is the new standard of care for the patient population.
 
SELECTED
LANGUAGE


Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the STAMPEDE and LATITUDE trials for patients with prostate cancer.

The phase III STAMPEDE and LATITUDE trials have changed the standard of care for patients with newly diagnosed metastatic hormone-sensitive prostate cancer, states Agarwal.

Both trials combined abiraterone acetate (Zytiga) plus prednisone plus standard androgen deprivation therapy, explains Agarwal. Given the data from the trial, abiraterone plus prednisone is the new standard of care for the patient population.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x